What next for Sequenom? - a cautionary tale
This article was originally published in Clinica
Executive Summary
Allegations of falsification or misrepresentation of scientific data are not unknown in the healthcare industry, however, what has become public knowledge still can be characterised as “occasional”. Only a few days ago, Sanofi-Aventis was able to breathe a temporary sigh of relief as a federal judge dismissed a class action relating to possible increased suicidality linked to its anti-obesity drug rimonabant. Despite it having been withdrawn from the European market just months after its initial launch and not having been approved by the US FDA, the judge found that the defendants had failed to identify any specific safety data that were omitted from Sanofi-Aventis’ public disclosures.